Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine and Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT06860594Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triapine in glioblastoma (GBM), astrocytoma and diffuse midline glioma (DMG), sponsored by National Cancer Institute. Primary endpoint: Incidence of dose-limiting toxicity at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
triapine
03
Conditions
glioblastoma (GBM)astrocytomadiffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT06860594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860594.